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Devastating human neuromuscular disorders have been associated to defects in the ATP
synthase. This enzyme is found in the inner mitochondrial membrane and catalyzes the
last step in oxidative phosphorylation, which provides aerobic eukaryotes with ATP. With
the advent of structures of complete ATP synthases, and the availability of genetically
approachable systems such as the yeast Saccharomyces cerevisiae, we can begin to
understand thesemolecular machines and their associated defects at themolecular level.
In this review, we describe what is known about the clinical syndromes induced by 58
different mutations found in the mitochondrial genes encoding membrane subunits 8 and
a of ATP synthase, and evaluate their functional consequences with respect to recently
described cryo-EM structures.
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INTRODUCTION
Mitochondria support aerobic respiration and produce the bulk of cellular ATP by oxidative
phosphorylation (OXPHOS) (Saraste, 1999). Electrons provided by the oxidation of fatty acids
and carbohydrates are shuttled to oxygen along four respiratory chain (RC) complexes (I–IV)
embedded in the inner mitochondrial membrane (IMM), producing water and releasing the energy
necessary to pump protons from the mitochondrial matrix to the intermembrane space (IMS). This
results in the formation of transmembrane electrochemical ion gradient across the IMM, also called
the proton-motive force (pmf ). The outer side of the IMM is positively charged (the p-side) while
the inner side is negatively charged (the n-side). The pmf enables the F1Fo ATP synthase to produce
ATP from ADP and inorganic phosphate (Boyer, 1997). The OXPHOS complexes contain ∼90
structural proteins of which 13 are encoded by the mtDNA in humans.
More than 150 distinct genetic mitochondrial dysfunction syndromes characterized by a
diminished OXPHOS capacity have been described (Tuppen et al., 2010; Hejzlarova et al., 2014;
Chinnery, 2015; Ng and Turnbull, 2015; Stewart and Chinnery, 2015; Xu et al., 2015). These diseases
affect at least 1 in 5,000 live human births (Skladal et al., 2003). Typical clinical traits include
visual/hearing defects, encephalopathies, cardiomyopathies, myopathies, diabetes, liver, and renal
dysfunctions (Table 1; Dimauro and Schon, 2003; Zeviani and Carelli, 2007; Vafai and Mootha,
2012). Many known cases result from alterations in mtDNA (∼15%, e.g., NARP, MILS, LHON),
which occur as a result of this DNA’s high susceptibility to mutations because of the nearby ROS
production and the poor effectiveness of the mitochondrial DNA repair system (Wallace, 2010).
More than 600 different point mutations and innumerable large-scale rearrangements of mtDNA
have been implicated in human diseases (Lott et al., 2013).
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TABLE 1 | Diseases and syndromes caused by mutations in ATP8 and ATP6.
Disease/Syndrome Phenotypes
Apical hypertrophic cardiomyopathy (AHCM)
and neuropathy
primary disease of the myocardium (the muscle of the heart) in which a portion of the myocardium is hypertrophied
(thickened) without any obvious cause, creating functional impairment of the cardiac muscle; neuropathy is damage to
or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of
health, depending on the type of nerve affected
Ataxia genetic disorders characterized by slowly progressive incoordination of gait and is often associated with poor
coordination of hands, speech, and eye movements, with full mental capacity
Autism neurodevelopmental disorder, characterized by impaired social interaction, verbal and non-verbal communication, and
restricted and repetitive behavior; noticeably affected by mitochondrial dysfunction which impairs energy metabolism
Charcot-Marie-Tooth syndrome (CMT) hereditary disorders that damage the nerves in arms and legs (peripheral nerves); symptoms usually begin in feet and
legs, but they may eventually affect hands and arms
Encephalopathy abnormal brain function or brain structure, symptoms may be mental or physical dysfunctions, depending on what part
of the brain is being affected
Epilepsy with Brain Pseudoatrophy brain disorder manifesting by seizures, dementia, convulsions, loss of control on muscles, difficulties with talking
Episodic Weakness muscular disorders (myopathies) that are only present after exercise or are exacerbated by exercise, skeletal muscle
diseases, may be accompanied by neurological symptoms
Hereditary Spastic Paraplegia (HSP) heterogeneous disorder characterized by lower extremity spasticity and weakness
Familial Bilateral Striatal Necrosis (FBSN) acute neurological syndrome associated with radiological findings, respiratory illnesses presenting with an array of
neurological findings, including axial ataxia, grimacing, mutism, head nodding, and high-pitched cry
Infantile cardiomyopathy severe, eventually fatal, cardiac arrhythmias, characterized pathologically by cardiac hypertrophy and by a distinctive
type of focal degeneration of the muscle cells, which lose their myofibrils, undergo marked mitochondrial hyperplasia,
become rounded in shape and enlarged, and resemble histiocytes
Leber Hereditary Optic Neuropathy (LHON) maternally inherited disease leading to acute bilateral blindness due to loss of the optic nerve and papillomacular
bundle nerve fibers, predominantly in young men
Left Ventricular HyperTrabeculation syndrome
(LVHT) (noncompaction)
myocardial abnormality of the apex, characterized by multiple, myocardial cotyledo-like protrusions and interwoven
strings, all lined by endocardium; in three quarters of the cases associated with neuromuscular disorders
Maternally Inherited Diabetes and Deafness
syndrome (MIDD)
form of diabetes that is often accompanied by hearing loss, especially of high tones, characterized by high blood sugar
levels (hyperglycemia) resulting from a shortage of the hormone insulin
Maternally Inherited Leigh Syndrome (MILS) early-onset progressive neurodegenerative disorder with a characteristic neuropathology consisting of focal, bilateral
lesions in one or more areas of the central nervous system, manifesting with (encephalopathy), lactic acidosis, seizures,
heart disease (cardiomyopathy), breathing (respiratory) abnormalities, and developmental delays
Mesial Temporal Lobe Epilepsies with
Hippocampal Sclerosis (MTLE-HS)
chronic neurological condition characterized by recurrent, unprovoked epileptic seizures (epilepsy) which originate in
the temporal lobe of the brain, its pathophysiological substrate is usually hippocampal sclerosis, the most common
epileptogenic lesion encountered in patients with epilepsy
Metabolic Syndrome (MS) disorder characterized by a group of metabolic abnormalities including hyperglycemia, hypertension, hyperlipaemia
and central obesity, which are the risk factors of cardiovascular disease and diabetes
Motor Neuron Syndrome (MNS) cognitive impairment, exercise intolerance, and progressive muscle weakness
Myopathy, Lactic Acidosis, and Sideroblastic
Anemia (MLASA)
mitochondrial disorder specific to skeletal muscle and bone marrow with myopathy, lactic acidosis, and sideroblastic
anemia with ringed sideroblasts
Neurogenic Ataxia Retinis Pigmentosa
syndrome (NARP)
mitochondrial disease affecting nervous system manifesting with pain in the arms and legs (sensory neuropathy),
muscle weakness, problems with balance and coordination (ataxia), vision loss caused by retinitis pigmentosa or
changes in the light-sensitive tissue that lines the back of the eye
Periodic paralyzes genetic diseases that lead to weakness or paralysis (rarely death) from common triggers such as cold, heat, high
carbohydrate meals, not eating, stress or excitement, and physical activity of any kind
Schizophrenia mental disorder, often characterized by abnormal social behavior and failure to recognize what is real
SpinoCerebellar Ataxia (SCA) ataxia that is due to dysfunction of the cerebellum
Tetralogy of Fallot (ToF) type of congenital heart disease, essentially a right-sided heart disease, with characteristic features of ventricular septal
defect, right ventricular outflow tract obstruction, aortic dextroposition, and right ventricular hypertrophy
This review focuses on mutations in the MT-ATP8 and MT-
ATP6 genes (further named ATP8 and ATP6) encoding subunits
8 and a of ATP synthase, respectively, that were identified in
patients with various disorders. We summarize what is known
about their clinical and functional consequences. Based on
recent high-resolution structures (Morales-Rios et al., 2015a;
Zhou et al., 2015; Hahn et al., 2016; Guo et al., 2017), we
define the topological locations of these mutations, which helps
understand their impact on ATP synthase structure, function and
assembly.
ATP SYNTHASE STRUCTURE AND
FUNCTION
Mitochondrial ATP synthase is a unique macromolecular rotary
machine of ∼625 kDa. It is composed of typically 17 different
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protein subunits (Figure 1) and organizes into a membrane-
extrinsic F1 catalytic and membrane-embedded Fo domains,
which are connected by a peripheral and central stalk (Allegretti
et al., 2015; Morales-Rios et al., 2015a; Zhou et al., 2015). The
matrix-oriented F1 is composed of a prominent (αβ)3 catalytic
head into which the γ δε central stalk rotor penetrates. The Fo
c-ring typically consists of identical c subunits (subunit 9 in
yeast). Together with subunit a, the c-ring shuttles protons across
the membrane. The Fo domain further consists of subunits 8
(alias A6L), b (4 in yeast), f, d, F6 (h in yeast), and OSCP that
together form the peripheral stalk connecting the catalytic head
with themembrane stator. Threemitochondria-specific subunits,
e, g, k, induce either directly or indirectly the formation of ATP
synthase dimers (Hahn et al., 2016) that self-assemble in longer
ribbons important for cristae formation (Parsons, 1963; Strauss
et al., 2008).
The ATP synthase harbors a unique rotary mechanism
driven by the pmf to translocate ions through Fo, to generate
FIGURE 1 | Cartoon representation of the yeast F1Fo ATP synthase. The view
is horizontally to the membrane shown in grayscale. The structure was drawn
according to (Hahn et al., 2016, PDB code 5FL7). For simplicity the structure is
shown without subunits e, f, g, I, and a truncated subunit b. The figure was
made in Pymol (The PyMOL Molecular Graphics System, Version 0.99,
Schrödinger, LLC), using the following color code: α, forest; β, split pea; γ ,
density; δ, cyan; ε, white; OSCP, red; b (= 4 in yeast), dirty violet; d, orange; h,
salmon; 8, green; a, blue; c-ring, yellow. The arrows indicate the path of
protons (see also Figure 4) and nucleotide conversion. For details see text.
rotation of its rotor and transmit torque into the F1 catalytic
head where finally ATP is synthesized and released. Subunit a
provides a pathway that involves a number of hydrophilic amino
acids, which allows protons to enter from the IMS (Figure 1).
Approximately in the middle of the membrane the proton can
bind to a highly conserved acidic residue of subunit c helix 2
(cH2) (cE59 in H. sapiens) located at the outer surface of the
c-ring. It has been suggested that the binding of a proton on this
carboxylate residue disrupts a previously established electrostatic
interaction of cE59 with a highly conserved, positively charged
arginine residue in subunit amembrane helix 5 (aH5) (aR159 in
H. sapiens; Vik and Antonio, 1994; Junge et al., 1997; Pogoryelov
et al., 2010; Guo et al., 2017). This arginine acts as an electrostatic
separator between the proton pathway from the IMS to the
middle of the membrane and a second, spatially separated
pathway that allows incoming protons still bound on the c-ring
glutamate to be released into the matrix (Mitome et al., 2010).
The operation direction of this process is primarily driven by
the ion gradient that causes a ratchet type mechanism of the
neutralized c-ring glutamate in the hydrophobic membrane,
which is energetically unfavorable and does not allow the back
stepping without externally applied force (Vik and Antonio,
1994; Junge et al., 1997). After an almost complete revolution
of the c-ring, the glutamate is deprotonated in the aqueous
exit channel (Pogoryelov et al., 2010). This channel is formed
by hydrophilic residues of the c-ring/subunit a interface at the
matrix side through which the protons can reach the matrix
(n-Side) (Allegretti et al., 2015; Morales-Rios et al., 2015a; Zhou
et al., 2015; Hahn et al., 2016; Guo et al., 2017). The c-ring
is tightly bound to the central stalk subunits γ δε, of which
subunit γ protrudes into the F1 catalytic head, which induces
cyclic conformational changes when rotating (Abrahams et al.,
1994). Consequently, ADP and Pi are sequentially converted
at the catalytic sites of the three subunits β , according to the
binding change mechanism (Boyer, 1997). Cryo-EM structures
of the bovine Bos taurus and yeasts Yarrowia lipolytica and
Saccharomyces cerevisiae F1Fo ATP synthases, that are basically
of the same subunit composition and structural construction
as the human enzyme, have been described recently [15–17].
These structures show a very similar overall architecture and
differ only with respect to the subunit c (9) stoichiometry (8
in mammals, 10 in yeasts), the loss of the dimerization domain
subunits (e/g/k) during purification (yeast) and the non-essential
and yeast specific subunits i and k (Zhou et al., 2015; Hahn
et al., 2016; Guo et al., 2017). It therefore has become feasible to
build reliable structural models of the membrane domain (Fo)
of the eukaryotic, mitochondrial, ATP synthase (Figure 1), and
to map the human disease-causing mutations at the molecular
level within the ATP synthase structure and to pin-point their
potentially adverse effects on the above-described mechanism.
YEAST AND HUMAN CELLULAR MODELS
OF mtDNA DISEASES
Human cells contain up to thousands copies of mtDNA (Miller
et al., 2003). Mutations in this DNA are highly recessive and
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usually co-exist with wild type mtDNA molecules, a situation
referred to as heteroplasmy. A mutational load above 60%
is usually required to induce a clinical phenotype (Stewart
and Chinnery, 2015). Given the high mutational rate of the
mitochondrial genome and the presence of numerous family
or population-specific polymorphisms, it can be difficult to
distinguish between a neutral mtDNA variant and a disease-
causing mutation. Additionally, the effects of deleterious mtDNA
mutations might be exacerbated by mtDNA nucleotide changes
that are not pathogenic per se and by unknown factors in nuclear
genetic background, i.e., the so-called modifier genes (Cai et al.,
2008; Swalwell et al., 2008). These features make it difficult from
patient’s cells and tissues to precisely know how specific mtDNA
mutations influence oxidative phosphorylation.
To better characterize the effects of mtDNA mutations,
homoplasmic cell lines, i.e. with a 100% mutational load, in
a defined nuclear genetic background are required. To this
end King and Attardi (King and Attardi, 1989) developed
an approach that used cybrid (cytoplasmic hybrid) cell lines
obtained by fusing enucleated cytoplasts from patient’s cells
with cells lacking mtDNA (ρ0). This approach was used to
evaluate the bioenergetics consequences of 11 ATP6 mutations
(Trounce et al., 1994; Majander et al., 1997; Nijtmans et al., 2001;
Carrozzo et al., 2004; Mattiazzi et al., 2004; Pallotti et al., 2004;
Jonckheere et al., 2008; Sikorska et al., 2009; Aure et al., 2013;
Blanco-Grau et al., 2013; Lopez-Gallardo et al., 2014; Hejzlarova
et al., 2015; Wen et al., 2016). Another approach exploits unique
features of S. cerevisiae. Mitochondria from this single-celled
fungus and humans show many similarities (Steinmetz et al.,
2002; Prokisch et al., 2004; Reinders et al., 2006; Pagliarini
et al., 2008; Rhee et al., 2013), and mitochondrial genetic
transformation can be achieved in this yeast in a highly controlled
fashion, by the biolistic delivery into mitochondria of in-vitro-
made mutated mtDNA fragments, followed by their integration
into wild type mtDNA by homologous DNA recombination
(Bonnefoy and Fox, 2001). Being unable to stably maintain
heteroplasmy (Okamoto et al., 1998), it is easy to obtain yeast
homoplasmic populations where all mtDNA molecules carry a
mutation of interest. Owing to its good fermenting capacity,
yeast models of human mitochondrial diseases can be kept alive
when provided with sugars like glucose even when oxidative
phosphorylation is completely inactivated (Baile and Claypool,
2013; Lasserre et al., 2015). This approach was used to investigate
the impact on ATP synthase of nine ATP6mutations identified in
patients (Rak et al., 2007; Kucharczyk et al., 2009a,b,c, 2010, 2013;
Kabala et al., 2014; Lasserre et al., 2015; Niedzwiecka et al., 2016;
Wen et al., 2016).
PATHOGENIC MUTATIONS IN ATP8 AND
ATP6
Subunits 8 and a are synthesized from a bi-cistronic mRNA
unit (Figure 2). The two genes show a 46 nucleotide overlap.
Thus, mutations in this unit can affect either subunit a or 8, or
both. Currently, 36 different ATP8 and ATP6 mutations with
a confirmed or suspected pathogenic character are recorded in
MITOMAP database (Figure 3). We here review 22 additional
mutations found in literature. The nucleotide and amino acid
changes induced by these mutations, and what is known about
their functional and clinical consequences is summarized in
Table 2.
Mutations Affecting Only Subunit 8
Tenmutations affecting only subunit 8were identified in patients
presenting with various disorders: epilepsy [m.8502A>T
(8N46I)] (Gurses et al., 2014); LVHT or MIDD [m.8381A>G
(8T6A)] (Perucca-Lostanlen et al., 2000; Finsterer et al., 2004);
brain pseudo-atrophy, episodic weakness and neurological
disorders [m.8393C>T (8P10S) (Galimberti et al., 2006),
m.8403T>C (8I13T) (Aure et al., 2013), and m.8411A>G
(8M16V) (Mkaouar-Rebai et al., 2010)], heart problems
[m.8481C>T (8P39L)] (Tansel et al., 2014); schizophrenia
[m.8463A>G (8Y33C), m.8510A>G (8K49E) andm.8519G>A
(8E52K)] (Ueno et al., 2009; Sequeira et al., 2015); and autism
[m.8472C>T (8P36L)] (Piryaei et al., 2012).
Mutations Affecting Both Subunits 8 and a
Three mutations affecting both subunits 8 and a [m.8528T>C
(8W55R + aM1T), m.8529G>A (8W55STOP + aM1I),
m.8558C>T (8P65S + aA11V)] were identified in patients
suffering from severe cardiomyopathies (Jonckheere et al., 2008;
Ware et al., 2009; Tang et al., 2010; Imai et al., 2016). A
fourth mutation affecting both proteins [m.8561C>G (8P66A+
aP12R)] was detected in individuals with features of cerebellar
ataxia, peripheral neuropathy and diabetes mellitus (Kytovuori
et al., 2016).
Mutations Affecting Only Subunit a
Most Frequent Mutations
• Two mutations at the same amino acid position of subunit
a, m.8993T>G (aL156R) and m.8993T>C (aL156P), were
identified in numerous patients presenting with the NARP or
MILS syndrome depending on the mutation load (Uziel et al.,
1997; Jonckheere et al., 2012). The first one was consistently
found to severely compromisemitochondrial ATP production,
with deficits of up to 90%. While most studies concluded this
was due to a block in proton translocation, some suggested
a less efficient coupling or defects in the assembly/stability
of ATP synthase (Tatuch et al., 1992; Trounce et al., 1994;
Houstek et al., 1995; Vazquez-Memije et al., 1998; Garcia
et al., 2000; Nijtmans et al., 2001; Carrozzo et al., 2004;
Mattiazzi et al., 2004; Pallotti et al., 2004; Morava et al., 2006;
Sgarbi et al., 2006; Baracca et al., 2007; Cortes-Hernandez
et al., 2007). Although its pathogenic character is firmly
established, the second mutation has less severe consequences
on ATP synthase with a 70% drop in ATP production mainly
because of a less efficient assembly or diminished stability of
subunit a (Vilarinho et al., 2001; Morava et al., 2006; Craig
et al., 2007; Kucharczyk et al., 2009a; Aure et al., 2013). In
addition to bioenergetic deficits, the two mutations lead to
an enhanced production of ROS and aberrant mitochondrial
morphologies that may contribute to the disease process
as well.
• Similar diseases were associated with two mutations at amino
acid position 217, m.9176T>G (aL217R), and m.9176T>C
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FIGURE 2 | ATP6 and ATP8 genes and sites of pathogenic mutations. The two coding sequences overlap, between positions 8527 and 8572 (cyan) of the human
mitochondrial genome. Start and end nucleotide numbers are indicated. The number of mutations (m) identified in patients and their positions are indicated. These
mutations are listed in Table 2.
(aL217P). The first one is extremely detrimental with a
block in subunit a assembly that leads to extreme clinical
phenotypes when highly abundant in cells and tissues. The
second one does not obviously compromise assembly of
subunit a indicating that it affects the functioning of ATP
synthase.
• The m.9185T>C (aL220P) mutation was identified in
individuals presenting with MILS, MNS, periodic paralyzes,
spinocerebellar ataxia syndromes (SCA) or CMT (Castagna
et al., 2007; Childs et al., 2007). Biochemical analyses revealed
a substantial drop (50–90%) in ATP production, and study
in yeast indicated that this mutation compromises the
functioning of ATP synthase (Kabala et al., 2014).
Other, Less Frequent, Mutations in Subunit a
• Eight additional mutations in subunit a [m.8597T>C (aI24T),
m.8618insT,m.8839G>C (aA105P),m.8989G>C (aA155P),
m.9025G>A (aG167S),m.9032T>C (aL169P),m.9127delAT
(aI201PfsX2) and m.9191T>C (aL222P)] were identified in
patients presenting with NARP or MILS disease. Although
they were thus far found only in a limited number of
individuals, biochemical investigations indicated that they
have detrimental consequences for ATP synthase. For
instance, the m.9191T>C was shown to dramatically affect
incorporation of subunit a in the yeast enzyme (Kabala et al.,
2014). These mutations are thus most likely pathogenic.
• The m.8969G>A (aS148N) mutation was found in a patient
presenting with MLASA (Burrage et al., 2014) and a 14-year-
old Chinese girl diagnosed with a severe nephropathy (Wen
et al., 2016). Biochemical investigations in yeast and human
cells revealed a block in the transfer of protons through the Fo.
• The m.8851T>C (aW109R) and m.8890A>G (aK122E)
mutations were identified in patients presenting with FBSN
and MS (De Meirleir et al., 1995; Honzik et al., 2013; Ye et al.,
2013). Studies with yeast revealed that m.8851T>C leads to
major drops (95%) in mitochondrial ATP synthesis owing to a
block in Fo-mediated proton transfer (Kucharczyk et al., 2013).
Them.9134A>G (aE203G) was identified in patient suffering
from MS accompanied with cardiomyopathy (Honzik et al.,
2012).
• The m.9035T>C (aL170P) was identified at high (>90%)
mutation load in 21 ataxia patients (Sikorska et al., 2009;
Pfeffer et al., 2012). Cybrids carrying this mutation had
reduced ATP levels (40–50% vs. controls) and produced 5–
7 times more ROS than control cells. Another mutation
m.8611insC (aL29PfsX36) was found in patient presenting
ataxia with encephalomyopathy (Jackson et al., 2017).
• Ten mutations [m.8668T>C (aW48R), m.8684C>T
(aT53I), m.8697G>A (aM57I), m.8836A>G (aM104V),
m.8950G>A (aV142I),m.9011C>T (aA162V),m.9016A>G
(aI164V), m.9029A>G (aH168R), m.9101T>C (aI192T),
and m.9139G>A (aA205T)] were identified in patients
presenting with LHON, a disease caused by defects in the
retinal ganglion cells and optic nerve that lead to blindness.
Two of them (m.9029A>G and m.9101T>C) were shown
to compromise oxidative phosphorylation by a yet-unknown
mechanism (Lamminen et al., 1995; Lopez-Gallardo et al.,
2014).
• The m.8932C>T (aP136S) and m.8527A>G (aM1V) were
identified in children with neuromuscular disorders (Felhi
et al., 2016). The first one was also identified in prostatic
cancer cells (Petros et al., 2005). In a yeast model of
this mutation, ATP synthase assembly/stability was found
substantially affected (Niedzwiecka et al., 2016).
• The m.9205delTA (aSTOP elimination) mutation was
identified in patients with a severe encephalopathy leading
to premature death. Since the stop codon of ATP6 overlaps
with the start codon of COX3, the expression of both genes is
compromised, which results in a lower content in complex IV
and ATP synthase (Jesina et al., 2004; Hejzlarova et al., 2015).
• The m.8719G>A (aG65STOP) and m.9058A>G (aT178A)
mutations were identified in patients presenting with LVHT
(Tang et al., 2010, 2013). Their biochemical consequences are
still unknown.
• Ten mutations [m.8701A>G (aT59A), m.8723G>A
(aR66Q), m.8794C>T (aH90Y), m.8843T>C (aI106T),
m.8902G>A (aA126T), m.8945T>C (aM140T),
m.9055G>A (aI177T), m.9071C>T (aS182L), m.9094C>T
(aL190F), andm.9160T>C (aY212H)] were found in patients
with autism or schizophrenia. Their consequences on ATP
synthase has not yet been investigated.
It is puzzling that mutations that cluster in specific regions
of ATP6 or ATP8 give rise to such a wide variety of
clinical symptoms (Table 1). These phenotypic differences may
be due to other unknown genetic variations in patients
within mitochondrial or nuclear DNA that could exacerbate
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FIGURE 3 | Sequence alignment of subunits a, b and 8 from a selected range of species. (A) Alignment of bacterial subunits b (b′ or b2 isoform) and mitochondrial
subunits 8. The sequences of subunit b are from Rhodobacter sphaeroides (R.s.), Ruegeria sp. (R.sp), Roseobacter denitrificans (R.d.), Jannaschia sp. (J.sp) and
Dinoroseobacter shibae (D.s.). The length of N- and C-termini extensions are given. The sequences of subunit 8 are from a selection of mammals and the yeast
species Schizosaccharomyces pombe (S.p.), Podospora anserina (P.a.), Yarrowia lipolytica (Y.l.), Saccharomyces cerevisiae (S.c.) and Candida glabrata (C.g.).
(B) Alignment of subunit a. Homo sapiens (H.s.), Bos taurus (B.t.). The sequences corresponding to overlapping ATP8 and ATP6 genes are marked in cyan as in
(Continued)
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FIGURE 3 | Figure 2. Peptide sequences removed in the mature form of yeast subunit a are marked in yellow. At the top and bottom, the arrows mark the locations
of the human mutations (Table 2) and the mutations modeled in S.c., respectively. The arrows are colored according to Figure 4. At the bottom, the secondary
structural elements are drawn according to PSIPRED prediction (2D) and a cryo-EM structure (3D) (Hahn et al., 2016).
or attenuate the consequences on health of defects in ATP
synthase subunits. Another important source of variability in
the clinical outcome likely resides in the levels of heteroplasmy
and different distributions of mtDNA mutations in cells and
tissues. Furthermore, in addition to a lack of ATP, defects in ATP
synthase may have multiple secondary effects, such as increased
production of ROS and changes in upstream metabolic processes
(Korshunov et al., 1997) that together will influence the disease
process unpredictably.
TOPOLOGY WITHIN THE FO OF
MUTATIONS IN SUBUNITS a AND 8
To define the topology of the ATP6 and ATP8 mutations
identified in patients, we used the recently published structures
of Y. lipolytica and S. cerevisiae ATP synthases (Hahn et al.,
2016; Guo et al., 2017); the complete model of subunits a, 8, and
the c-ring is shown in Figure 4. The amino acid alignments in
Figure 3 establish the correspondences with human subunits a
and 8 amino acids.
Subunit a Mutations
Helix 5 of subunit a (aH5) is kinked due to the presence of proline
at position 153, a residue well-known for its propensity to bend
or break alpha helices owing to its inability to participate fully
in protein backbone hydrogen bonding. aP153 enables aH5 to
follow the curvature of the c-ring and seal the two hydrophilic
pockets that connect the a/c-ring interface to the intermembrane
and matrix spaces. Five substitutions from hydrophobic alanine
or leucine residues into proline are located on aH5 (aH5) in
proximity to the essential aR159 residue (aA105P, aA155P and
aL156P) that faces the proton binding glutamate of the c-ring,
or close to aH168/aE203 in the proton entry channel (aL169P,
aL170P). These mutations may distort or break aH5. Those
at positions 155 and 156 at one helix turn from aR159 may
compromise the ion translocation mechanism, for example by
ion short circuiting (Mitome et al., 2010) or by preventing aR159
to interact with the c-ring glutamate due to its structurally
shifted position. On aH6, the aL217P, aL220P, and aL222P
mutations are on the edge of the exit channel close to the
matrix. Their severe functional consequences possibly result
from a change in the topology of the nearby aD224 residue
that was suggested to be of critical importance for the exit of
protons toward the mitochondrial matrix (Guo et al., 2017).
Similarly, the aP136S change in the loop connecting aH4 and
aH5 possibly alters the accessibility of protons in this region of
subunit a.
The extremely detrimental consequences of aL217R on ATP
synthase assembly/stability (Kucharczyk et al., 2009b) possibly
results from the inability of subunit a to pack tightly owing
to replacement of a hydrophobic residue with a bulkier and
positively charged one within the membrane. The absence of
proton conduction induced by the aL156R mutation at the
a/c-ring interface (Rak et al., 2007), without any defect in
ATP synthase assembly, may be caused by the inability of
protons to exit from the ring or by electrostatic or steric
hindrance that prevent rotation of the ring. Being located near
the N-terminal side of aH5, the block in proton translocation
induced by the aS148N mutation (Wen et al., 2016) possibly
results from obstruction of the proton exit pore. The detrimental
consequences of aH168R (Lopez-Gallardo et al., 2014) are
not surprising considering its location in the p-side cleft in
the proximity of the c-ring. This positive charge cuts off the
connection of the p-side to the c-ring. A similar effect on the
n-side of the membrane may result from the aW109R, where
aH5 and aH6 diverge. A mutation at this position has an
impact in proton translocation without impacting ATP synthase
assembly/stability (Kucharczyk et al., 2013), indicating that this
location of subunit a is close to the pathway along which
protons are evacuated into the matrix. The clinical consequences
of aK122E probably also result from a less efficient proton
conduction toward the matrix.
While aM140T, aG167S, aA177T, aI192T, aA205T, and
aY212H decrease the hydrophobicity of the a/c-ring interface,
it is less obvious from our structural model to predict the
consequences of other mutations that replace hydrophobic to
non-charged hydrophilic residues (aI24T, aI106T, aA126T) or
vice-versa (aT53I, aT59A, aT178A, aS182L) and those that
lead to small hydrophobicity changes (aM57I, aM104V, aV142I,
aA162V, aI164V, aL190F). However, meaningfully, most are
within helices aH4-6 that are important for the movement of
protons through Fo.
Subunit 8 Mutations
The yeast subunit 8 has an overall kinked helical structure with a
N-terminal transmembrane helix (8H1) and a short helix (8H2)
exposed to the matrix. 8H1 is flanked by subunit i and aH1
(Hahn et al., 2016; Guo et al., 2017). At the distal stator side,
8H1 is exposed toward the dimer interface in a bent lipid bilayer
region. At the base of the peripheral stalk, the C-terminus of 8H2
is nestled inside the helical domain composed by subunits b, d
and f. In vertebrates, no secondary structures are predicted in
the C-terminal half of subunit 8 and subunit f displays only 18%
identity with its yeast homolog, which explains why they could
not be modeled from the bovine ATP synthase cryo-EM density
map (Zhou et al., 2015). Subunit 8 shows at its N-terminus a
conserved 4 amino acid motif (MPQL, Figure 3). This motif and
8H1 share significant homologies with one of the two subunits b
(isoform b′ or b2) from α-proteobacteria (Figure 3A), indicating
that subunit 8 (A6L) is an evolutionary vestige of bacterial
subunit b that remained mtDNA encoded (Hahn et al., 2016).
Subunit 8 stabilizes in the membrane the helical N-terminal
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FIGURE 4 | Positions of human neurodegenerative disease-causing mutations in the structure of the yeast mitochondrial ATP synthase subunits a and 8 (human
A6L). The views are from the matrix (A,B) and from the IMS (C,D) with detailed views in the IMS entry channel (B) and in the matrix exit channel (D). On (E,F),
showing views along the membrane plane from outside the Fo stator and from the c-ring, respectively, the membrane borders are indicated as black lines. Subunits a,
8, and c are shown in blue, green, and yellow, respectively. The model is based on structural data from the Y. lipolytica and S. cerevisiae structures (Hahn et al., 2016;
Guo et al., 2017). The positions of mutations, which have been found in human neurodegenerative diseases, are marked in white, red, blue, pink, orange and black for
(Continued)
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FIGURE 4 | hydrophobic, negatively and positively charged, uncharged polar, proline and special residues, respectively. The mutations are labeled according to their
positions in human subunit a listed in Table 2. The arrows indicate the path of protons in ATP synthesis direction. The conserved arginine (h.s. aR159, S.c. aR186) on
helix aH5 is indicated by stick model; its orientation is randomly chosen. The figure was drawn with UCSF ChimeraX (Goddard et al., 2017).
half of subunit a (Hahn et al., 2016). Four of the mutations
identified in patients (8T6A, 8P10S, 8I13T, 8M16V) cluster at the
N-terminal region of helix 8H1 in proximity to aH4, suggesting
that they may affect the stability of subunits a and 8 (Hahn et al.,
2016). The six other mutations identified in patients (8Y33C,
8P36L, 8P39L, 8N46I, 8K49E, 8E52K) are in the matrix-exposed
helix 8H2. These mutations might affect the flexibility of the
outer stalk, and thereby compromise the stability of Fo and/or,
indirectly, the ion translocation mechanism or ATP synthase
assembly process. This hypothesis is supported by the reduced
functionality and stability of ATP synthase in these patients
and by various studies on subunit b in the bacterial enzyme
(Schneider and Altendorf, 1984, 1985; Wehrle et al., 2002; Greie
et al., 2004).
ATP SYNTHASE DIMERS AND
MITOCHONDRIAL MORPHOLOGY
The mitochondrial ATP synthase exists as dimers (Schagger and
Pfeiffer, 2000; Paumard et al., 2002) that associate into rows
that contribute to cristae formation (Davies et al., 2011; Hahn
et al., 2016). The mutations in subunits 8 and a often correlate
with pathological forms of mitochondria cristae as for example
seen in the Leigh syndrome (Kucharczyk et al., 2009b). The
defects caused by these mutations therefore not only affect the
ATP synthase function but they can also affect the assembly
process. The reduced amount, or lack thereof, of native and
completely assembled ATP synthase dimers would certainly affect
cristae formation, which is crucial for the accommodation of the
OXPHOS respiratory chain complexes and the ATP synthase.
This explains some of the pathologic forms of mitochondria
found in the diseases and syndromes described in this review.
CONCLUSIONS
Diseases associated to mutations in the mitochondrial ATP6 and
ATP8 genes are particularly challenging to study due to factors
like heteroplasmy, complex inheritance, variable penetrance, and
interactions with (e.g., nuclear) modifier genes, which makes it
difficult to verify their pathogenicity. The possibility to create
and keep alive homoplasmic strains of S. cerevisiae with defined
mtDNA mutations in a controlled nuclear genetic background
makes it possible to study their functional consequences. With
the recently obtained cryo-EM structures of F1Fo ATP synthase
from various mitochondrial origins it has become feasible to
map mutations in ATP6 and ATP8 at the molecular level
within the Fo. These “open eyes” provide the chance for a
completely new level of understanding of how the mutations
may affect ATP synthase structure, assembly, and mechanism.
This knowledge also enables to evaluate the observed pathogenic
forms of mitochondrial morphology that are associated with
these syndromes on the structural level, from the mutation at the
molecular level to its associated consequences at the macroscopic
scale of the organelle. The recent technical advances enabling
the structural analysis of macromolecular complexes by cryo-
EM (Kühlbrandt, 2014), the advent of complete structures of
ATP synthases (Allegretti et al., 2015; Morales-Rios et al., 2015b;
Zhou et al., 2015; Hahn et al., 2016; Sobti et al., 2016; Guo et al.,
2017) and the availability of genetically approachable systems
like S. cerevisiae are just the first steps in these new shoes; they
will considerably improve the comprehension of human diseases
associated to defects in this key mitochondrial enzyme. We are
still at the beginning of understanding these complex processes.
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